201 related articles for article (PubMed ID: 30660076)
1. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
[TBL] [Abstract][Full Text] [Related]
2. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ
Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
[TBL] [Abstract][Full Text] [Related]
3. Exploration of Morphological Features of Clear Cell Renal Cell Carcinoma With
Liu Y; Li Y; Xu H; Zhou L; Yang X; Wang C
Int J Surg Pathol; 2023 Dec; 31(8):1485-1494. PubMed ID: 36911986
[TBL] [Abstract][Full Text] [Related]
4. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.
Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Parasramka M; Cheville JC; Wu KJ; Frenkel E; Rakheja D; Stefanius K; Brugarolas J; Parker AS
Urol Oncol; 2015 Jan; 33(1):23.e9-23.e14. PubMed ID: 25465300
[TBL] [Abstract][Full Text] [Related]
5. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma.
Chakiryan NH; Hajiran A; Kim Y; Aydin AM; Zemp L; Katende E; Nguyen J; Fan W; Cheng CH; Lopez-Blanco N; Chahoud J; Spiess PE; Fournier M; Dhillon J; Wang L; Moran-Segura C; Mulé J; Du D; Yoder SJ; Berglund A; Teer JK; Manley BJ
Eur Urol Focus; 2022 May; 8(3):784-793. PubMed ID: 33994165
[TBL] [Abstract][Full Text] [Related]
6. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
[TBL] [Abstract][Full Text] [Related]
7. Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.
Manley BJ; Zabor EC; Casuscelli J; Tennenbaum DM; Redzematovic A; Becerra MF; Benfante N; Sato Y; Morikawa T; Kume H; Fukayama M; Homma Y; Ogawa S; Arcila ME; Voss MH; Feldman DR; Coleman JA; Reuter VE; Motzer RJ; Russo P; Hsieh JJ; Hakimi AA
Eur Urol Focus; 2017 Oct; 3(4-5):421-427. PubMed ID: 28753773
[TBL] [Abstract][Full Text] [Related]
8. PBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell Carcinoma.
Chowdhury B; Porter EG; Stewart JC; Ferreira CR; Schipma MJ; Dykhuizen EC
PLoS One; 2016; 11(4):e0153718. PubMed ID: 27100670
[TBL] [Abstract][Full Text] [Related]
9. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma.
Joseph RW; Kapur P; Serie DJ; Eckel-Passow JE; Parasramka M; Ho T; Cheville JC; Frenkel E; Rakheja D; Brugarolas J; Parker A
Cancer; 2014 Apr; 120(7):1059-67. PubMed ID: 24382589
[TBL] [Abstract][Full Text] [Related]
10. PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study.
Chang Q; Sun J; Zhao S; Li L; Zhang N; Yan L; Fan Y; Liu J
Aging (Albany NY); 2023 Nov; 15(23):13753-13775. PubMed ID: 38048211
[TBL] [Abstract][Full Text] [Related]
11. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Ricketts CJ; De Cubas AA; Fan H; Smith CC; Lang M; Reznik E; Bowlby R; Gibb EA; Akbani R; Beroukhim R; Bottaro DP; Choueiri TK; Gibbs RA; Godwin AK; Haake S; Hakimi AA; Henske EP; Hsieh JJ; Ho TH; Kanchi RS; Krishnan B; Kwiatkowski DJ; Liu W; Merino MJ; Mills GB; Myers J; Nickerson ML; Reuter VE; Schmidt LS; Shelley CS; Shen H; Shuch B; Signoretti S; Srinivasan R; Tamboli P; Thomas G; Vincent BG; Vocke CD; Wheeler DA; Yang L; Kim WY; Robertson AG; ; Spellman PT; Rathmell WK; Linehan WM
Cell Rep; 2018 Apr; 23(1):313-326.e5. PubMed ID: 29617669
[TBL] [Abstract][Full Text] [Related]
12. Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma.
Wei X; Choudhury Y; Lim WK; Anema J; Kahnoski RJ; Lane B; Ludlow J; Takahashi M; Kanayama HO; Belldegrun A; Kim HL; Rogers C; Nicol D; Teh BT; Tan MH
Sci Rep; 2017 Aug; 7(1):7342. PubMed ID: 28779136
[TBL] [Abstract][Full Text] [Related]
13. Sharing the initial experience of pan-cancer panel analysis in high-risk renal cell carcinoma in the Korean population.
Suh J; Jeong CW; Choi S; Ku JH; Kim HH; Kim K; Kwak C
BMC Urol; 2020 Aug; 20(1):125. PubMed ID: 32811483
[TBL] [Abstract][Full Text] [Related]
14. Germline BAP1 mutations predispose to renal cell carcinomas.
Popova T; Hebert L; Jacquemin V; Gad S; Caux-Moncoutier V; Dubois-d'Enghien C; Richaudeau B; Renaudin X; Sellers J; Nicolas A; Sastre-Garau X; Desjardins L; Gyapay G; Raynal V; Sinilnikova OM; Andrieu N; Manié E; de Pauw A; Gesta P; Bonadona V; Maugard CM; Penet C; Avril MF; Barillot E; Cabaret O; Delattre O; Richard S; Caron O; Benfodda M; Hu HH; Soufir N; Bressac-de Paillerets B; Stoppa-Lyonnet D; Stern MH
Am J Hum Genet; 2013 Jun; 92(6):974-80. PubMed ID: 23684012
[TBL] [Abstract][Full Text] [Related]
15. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis.
Rosellini M; Mollica V; Marchetti A; Coluccelli S; Giunchi F; Tassinari E; Ricci C; Fiorentino M; Tallini G; De Biase D; Massari F
Pathol Res Pract; 2024 Feb; 254():155142. PubMed ID: 38277752
[TBL] [Abstract][Full Text] [Related]
16. Morphological characteristics of SETD2-mutated locally advanced clear cell renal cell carcinoma: Comparison with BAP1-mutated clear cell renal cell carcinoma.
Takeda K; Bastacky S; Dhir R; Mohebnasab M; Quiroga-Garza GM
Ann Diagn Pathol; 2024 Feb; 68():152223. PubMed ID: 37976977
[TBL] [Abstract][Full Text] [Related]
17. Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer.
Williamson SR; Gill AJ; Argani P; Chen YB; Egevad L; Kristiansen G; Grignon DJ; Hes O
Am J Surg Pathol; 2020 Jul; 44(7):e47-e65. PubMed ID: 32251007
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive molecular characterization of clear cell renal cell carcinoma.
Cancer Genome Atlas Research Network
Nature; 2013 Jul; 499(7456):43-9. PubMed ID: 23792563
[TBL] [Abstract][Full Text] [Related]
19. Integrated genomic analysis identifies subclasses and prognosis signatures of kidney cancer.
Christinat Y; Krek W
Oncotarget; 2015 Apr; 6(12):10521-31. PubMed ID: 25826081
[TBL] [Abstract][Full Text] [Related]
20. Clear cell renal cell carcinoma with
Lee J; Thuzar M; DiPoto-Brahmbhatt AC; Chaudoir C; Tanner A; Fazili T; Yu X; Constantinescu M; Yeh YA
Am J Clin Exp Urol; 2023; 11(5):429-434. PubMed ID: 37941648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]